Preface
Neural tube defects (NTDs) are a complex developmental trait in which several genes, interacting with environmental factors, create the phenotype. In the United States, the rate of NTDs has been repor~ed to range from 4 to 10 per 10,000 live births. Currently, in the United States, the two most common types of NTDs, anencephaly and spina bifida, which occurs in varying degrees of severity, affect approximately 4000 pregnancies per annum, resulting in the birth of 2500 to 3000 children manifesting one or the other of these conditions. Nevertheless, it has been proposed that 50-70% of the defects comprising this constellation of conditions could be prevented with daily intake of 400 !lg of folic acid throughout the periconceptional period. In this regard, The Centers for Disease Control and Prevention (CDC) recommended, in 1991, that women who have experienced a pregnancy affected by NTDs who are planning a new pregnancy consume 400 !lg of folic acid daily beginning at least one month prior to conception and continuing through the first three months of pregnancy. In addition, in 1992, the US Public Health Service (USPHS) recommended that all women of reproductive age consume 400 !lg of folic acid per diem. In 1996, the US Food and Drug Administration authorized and then required (1998) that enriched grain products be supplemented with folate. Also in 1998, the Institute of Medicine (IOM) recommended that all women of childbearing potential consume 400 !lg of synthetic folic acid per day from fortified foods and/ or a supplement in addition folate obtained from a varied diet.
These actions resulted in a significant decrease in the incidence of NTDs despite the 1998 report that only 29% of US women complied with the USPHS and IOM recommendations. Thus, in women receiving prenatal care, the rate decreased more than 19% (from 3. 78 I 10,000 live births to 3.05/10,000) while in women receiving prenatal care only during the third trimester or none at all, the rate decreased approximately 13% (from 5.34/10,000 live births to 4.65/10,000) .
The greatest need for folate occurs during pregnancy. During development, as the number of rapidly dividing cells increases, the requirement for folate increases. The situation is complicated by decreased absorption and increased clearance of folate during pregnancy. By the third trimester, the requirement for folate has almost doubled. In addition to NTDs, periconceptional folic acid supplementation reduces the occurrence of several human congenital malformations including craniofacial and heart defects. In the United States, because normal diets seldom supply the 400 !lg per diem of folate required during pregnancy, 20-25% of otherwise normal pregnancies are associated with low-serum folate levels. During July and August 1998, a survey was conducted to assess knowledge of the benefits of adequate folic acid consumption among women of childbearing age in the United States. The results were compared to those obtained from a similar survey conducted in 1995. The 1998 findings revealed that only 7% of women knew that folic acid should be taken prior to pregnancy to reduce the risk of NTDs. It is to be noted that, although recommendations regarding folic acid consumption were issued by health authorities in anumber of countries in the early 1990s, assessment of periconceptional intake of folic acid revealed a disappointingly low level of compliance. Therefore, it appears that, regardless of food fortification policies, continued promotion of the benefits of folic acid supplementation to optimize the folate status of women of child-bearing age will be required in most countries. Indeed, although periconceptional folate supplementation has been encouraged in the United Kingdom since the early 1990s, no concurrent decline in NTD pregnancies has been observed by regional congenital anomaly registries. Conceivably, additional nutritional inadequacies also may be involved. However, these have not been extensively researched. In this regard, it is of interest to note that, in California between 1989 and 1991, the interaction between maternal preconceptional dietary and supplemental zinc intake and the risk of NTDs was investigated in a population-based case-control study. Four hundred and thirty (430) NTD-affected fetuses/infants and 429 randomly selected, non-malformed infants comprised the case and control populations. The preconceptional use of vitamins, minerals, and food supplements was reported by the mothers who completed a 98-item food frequency questionnaire. Phytateintake, a dietary constituent known to interfere with zinc absorption, appeared to negatively impact the zinc/NTD association. It was observed that increased servings of animal products, which are the most bioavailable food source of zinc, were associated with a reduced risk for NTDs. Risk estimates for zinc intake changed little after controlling for multiple sociodemographic factors and total folate intake, but were attenuated after controlling for nutrients highly correlated with dietary sources of zinc. The analyses indicated that risk of NTDs in fetuses and infants decreased with increasing maternal preconceptional zincintake. However, it remains unclear whether increased zinc intake or other nutrients or combinations of nutrients that may be highly correlated with dietary zinc intake are causally associated with reduced NTD risk.
Homocysteine status also appears to play a role in NTDs. Homocysteine, a sulfur-containing amino acid is generated through the demethylation of methionine. It is metabolized via three principal routes. The predominant pathway is selected by physiological need. Thus, homocysteine can be metabolized to cysteine by transsulfuration or remethylated to methionine or hydrolyzed to a-ketobutyrate, ammonia, and H2S. Regulation of the plasma level of homocysteine is dependent on nutrient uptake, especially uptake of folate and vitamins B6 (pyridoxine) and B12 (cobalamin). In addition, its metabolism is affected by genetic individuality. Excess levels of homocysteine are thrombophilic and damage the vascular endothelium. In adult populations, total plasma homocysteine (tHey) is an established clinical risk factor for coronary artery disease as well as other arterial and vasaocclusive diseases. These vascular effects appear to be related to its role as a teratogen in the pathogenesis of NTDs and other developmental defects since genetic variants resulting in hyperhomocysteinemia are associated with NTDs. Thus, genetic variation in folate metabolic genes is expected to contribute to the risk of NTDs.
The observation that homocysteine and vitamin Bu levels are independent predictors of NTD risk suggested that the gene encoding methionine synthase might play a role in the induction of NTDs. Methionine synthase catalyzes the vitamin Bu-dependent conversion of homocysteine and 5-methyltetrahydrofolate to methionine and tetrahydrofolate. However, tests of an association between specific methionine synthase alleles and NTDs indicated that inherited variations in the gene do not contribute to NTD risk, at least not in the population studied. However, impairment of folate and vitamin B12 metabolism has been observed in families with NTDs. Therefore, it is conceivablethatgeneticvariants/mutantsofenzymesinthehomocysteine remethylation pathway might act as predisposing factors contributing to NTD risk. The first polymorphism discovered that was associated with increased NTD risk was the 677C-> T mutation (A222V) in methylenetetrahydrofolate reductase (MTHFR). It is to be noted that this variant also has been associated with increased risk of nonsyndromic orofacial clefts. A polymorphism, 66A->G (122M), in the gene that encodes the enzyme, methionine synthase reductase (MTRR), that activates vitamin B12-dependent methionine synthase, also has been reported. This mutation has an allelic frequency of 0.51 and increases the risk of NTDs when vitamin B12 status is low. In addition, in the presence ofthe 677C-> T mutant MTHFR genotype, the 66A->G (122M) MTRR mutant increases the risk of NTDs under conditions of adequate vitamin B12. When the genotype and B12 status of 56 children with spina bifida and 58 mothers of spina bifida children were compared to control groups consisting of 97 children and 89 mothers, the spina bifida cases and associated mothers were approximately twice as likely to possess the homozygous 66A->G (I22M) MTRR mutant genotype than the control groups. But, the difference was not statistically significant. However, the risk for homozygous 66A->G (122M) MTRR mutant genotype mothers with low B12 status to deliver a child with spina bifida increased approximately fivefold [odds ratio (OR) = 4.8, 95%; CI = 1.5-15.8], while the OR for spina bifida in children with this combination was 2.5 (95%; CI = 0.63-9.7). On a background of combined MTHFR and MTRR homozygous mutant genotypes, children had a fourfold increase in risk (OR= 4.1, 95%; CI = 1.0-16.4) of manifesting spina bifida while mothers had a threefold increase in risk (OR= 2.9, 95%; CI = 0.58-14.8) in delivering a child with this condition. Clearly, the interaction between vitamin B12 deficiency and the mutant MTHFR and MTRR genotypes indicates a multifactorial induction of NTDs. However, the mechanism is complex and unresolved. Furthermore, the MTHFR 677C-> T and MTRR 66A->G mutations are each associated with increased risk of Down syndrome. In the presence of both mutations, the risk is even greater.
It is well known that drugs and other chemicals can induce birth defects in humans. For example, pharmaceuticals such as valproic acid and other antiepileptic drugs that interfere with folate metabolism can induce NTDs. Therefore, a question worth considering is: Is low folate status during pregnancy a factor that increases or contributes to an increase in the risk of induction of NTDs and other birth defects from exposure to ambient levels of environmental xenobiotics? Unfortunately, this is a public health issue for which we have little information. Therefore, to gain further insight into the etiology of NTDs as well as all other birth defects that affect so many for their lifetime, continued research on the role of folate and other nutrients is imperative. The editors believe that the research data gathered by the contributors to this work are a step in the right direction. As in many areas of human developmental biology, the use of animal model systems may be of considerable benefit in attempting to understand the role of folate in prevention of neural tube defects (NTD). At present, direct study of prenatal human development is limited because of ethical considerations and the paucity of embryonic material available. Model systems provide several advantages, including the ability to study early stages of embryonic development in terms of morphology, biochemistry, and molecular biology. Potential teratogenic and therapeutic agents can be tested in a controlled environment to examine their effects on developmental processes and their relationship to folate metabolism. In addition, use of in vitro embryo culture methods enables the effect of such agents to be tested in the absence of potentially confounding maternal factors.
Increasingly, the animal model of choice is the mouse, although several others, notably the rat and chick, have been used, each with its own advantages. Studies of the mouse benefit from the vast amount of genetic data that has accumulated in recent years. Among the vertebrates, the mouse is second only to human in our understanding of its genetics. Hence, the mouse genome can now be manipulated by gene targeting and transgenic approaches, providing powerful tools for understanding the function of genes that may be involved in all aspects of developmental biology. Moreover, advances in mouse genetics have enabled the identification of the defective genes in many of the naturally occurring mutant strains of mice that have previously been identified as providing particularly useful models for human diseases. Added to this is our increasing ability to study, in the mouse, the many key Overall, therefore, the mouse provides an excellent model system for studies of mammalian development with a view to extrapolation to human developmental disease.
When considering folate-related defects specifically, the use of animal models circumvents three major problems that would hamper the study of genetic or environmental factors directly in humans:
1. Limitation of the availability of early embryonic material. The availability of naturally occurring or targeted mutant mouse strains provides the opportunity to study the effects of single or multiple known genes at early stages of development when human embryonic material is scarce. Where abnormalities of folate metabolism are detected, they can be correlated with both the developmental defect and the gene whose product is abnormal. Similarly, teratogeninduced defects can be reproducibly generated to allow analysis of embryos at different developmental stages. 2. Variability in environmental factors. The occurrence ofNTD is determined by both genetic and environmental factors ( 1,2). Studies of the role of folate in human development are frequently complicated by the presence of many coexisting variables such as maternal age, diet, folate status, vitamin B 12 levels, and exposure to potential teratogens ( 3, 4 ) . The ability to maintain mice under more strictly defined conditions (e.g., with uniform diet and maternal age) reduces this inherent variability and facilitates analysis of particular etiological factors. Moreover, the relatively large size of mouse litters enables comparisons among wild-type, heterozygous, and homozygous mutant embryos within a single maternal environment. This is particularly useful when studying gene-environment interactions. 3. Variability in genetic background. The incidence of NTD is known to be affected by multiple genetic factors ( 3 ) , although very few of these genes have yet been identified in humans. In the mouse, NTD can result from single-gene defects, but with a major influence of the genetic background. Such background effects can probably be attributed to the action of "modifier" genes that are polymorphic between different mouse strains or human populations. In humans, the C677T polymorphism of methylene tetrahydrofolate reductase (MTHFR) is associated with an increased risk of NTD in some populations but not in others (5) (6) (7) (8) .
Although the apparent population differences may have partly resulted from environmental factors or from differences in study methodology (9) , the effect of the MTHFR polymorphism is probably also modified by other genes that differ between populations. Experimental variability associated with genetic background effects can be avoided in mouse studies by the use of the many genetically defined inbred strains that are now available. These strains permit the analysis of single-gene or teratogenic effects in the absence of additional genetic variation and also facilitate the search for modifier genes that may predispose to, or protect individuals from, NTD.
The following sections review our current understanding of the role of folate in relation to NTD and other developmental defects, as revealed by the analysis of mouse models.
GENETIC MODELS AS SOCIA TED WITH FOLATE METABOLISM
There are now more than 60 mouse genetic models in which NTD have been described as part of the mutant phenotype ( 10,11 ). The models can be categorized into ( 1) those characterized by the persistent presence of an open neural tube (i.e., comparable to the human NTD anencephaly and meningomyelocele) and (2) those in which the neural tube closes but develops abnormally in various ways. The relevance of this second group of defects to human NTD is unclear and, here, we concentrate on the first group as examples of defective neural tube closure. In particular, we focus on those models in which gene mutations cause defects where folate metabolism is implicated either in the pathogenetic mechanism or in providing protection against development of the NTD (Table 1 ) .
In addition to mouse strains, for which the nature of the mutant gene is known, there are a number ofnaturally occurring strains in which the mutant gene has not yet been identified. Characterization of these genes should give further information about the pathways with which folic acid interacts and will provide further candidate genes to be analyzed in human NTD cases.
Axial Defects
In the axial defects (Axd) mutant mouse, open spinal NTD and tail flexion defects are observed in presumed homozygous mice among the offspring of heterozygote crosses ( 12). The mutation does not affect mean litter size or resorption rate, suggesting that Axd does not cause lethality. Tail defects are also observed in some heterozygotes and seem likely to result from delayed closure of the low spinal neural tube ( 12). As in several other mouse models, genetic background has a significant effect on the penetrance of the defect, with approximately half of the heterozygotes displaying a tail phenotype on the most susceptible background (12, 13) .
In terms of folate-preventable NTD, the Axd mouse does not provide an ideal model, as there is no effect of maternal supplementation with folinic acid or vitamin B 12 ( 14). In contrast, maternal methionine supplementation is reported to reduce the incidence of caudal NTD among the offspring of heterozygous crosses by approx 40% (13, 14 ) . This may indicate an abnormality in a folate-related pathway because 5-methyl tetrahydrofolate is the one-carbon donor for conversion of homocysteine to methionine by methionine synthase (Fig. 1, reaction I ). However, a simple methionine deficiency caused by a defect in methionine synthase appears unlikely, as plasma methionine levels are normal in Axd heterozygous females. A defect in homozygous embryos cannot be excluded, although this does not appear to have been tested ( 14).
Although methionine treatment has a protective effect against caudal NTD in Axd mice, the effect on neural tube closure appears to differ at more cranial levels because a few methionine-treated embryos develop exencephaly ( 13 ). As the genotype of embryos was not determined in these studies, it is unclear whether Axd mutants exhibit an increased susceptibility to cranial NTD. Alternatively, methionine may have had a deleterious effect on cranial neural tube closure in the Axd study, as also noted in splotch mice ( 15). 
CARTlKNOCKOUT
Gene targeting has been used to generate mice with a null mutation in Cart], a homeobox-containing gene that encodes the transcription factor, cartilage homeoprotein 1 ( 16, 17) . Homozygous Cart] mutant mice develop cranial NTD and die shortly after birth. The penetrance is influenced by genetic background with a maximum NTD incidence of 100% on a 129/ SvEv strain background ( 17). Cranial NTD result from failure of closure at the prospective forebrain/midbrain boundary, so called Closure 2. Failure of neural tube closure is thought to be the result of a reduction in the number of mesenchymal cells in the forebrain of homozygous mutant embryos at embryonic day 9 (E9). This deficit appears to result from an increase in cell death and correlates with the forebrain-specific expression of Cartl in the cranial mesenchyme. Cart] expression is absent from the E9 midbrain mesenchyme, which is histologically normal. Interestingly, however, the neural folds do not close in the midbrain, raising the possibility either of undetec-ted, low-level Cart] expression in the midbrain or of an influence from neighboring brain regions.
The deleterious effect of the Cart] mutation is greatly reduced by folic acid supplementation. Treatment by intraperitoneal injection during the first half of gestation reduced the incidence of NTD by approx 60% ( 17), although all the rescued mice died shortly after birth, indicating that there are residual defects that are not prevented by folic acid. Because treated litters were not examined during development, it is unclear whether folic acid treatment corrects the deficiency in forebrain mesenchyme. Folic acid may act to correct an abnormality of folate metabolism caused by loss of Cartl function. Alternatively, the protective effect may be unrelated to the underlying defect. For example, if Cart] deficiency causes mesenchymal cells to die, NTD could be prevented if folic acid serves to stimulate proliferation of the remaining mesenchymal cells.
Crooked Tail
Heterozygous crooked tail ( Cd) mutant mice exhibit characteristic tail defects. Homozygotes display a range of phenotypes that include early embryonic lethality and exencephaly, whereas remaining mice are small in size and have vertebral skeletal defects ( 18, 19 ) . The risk of exencephaly is approximately twice as high in females as in males, mimicking the female preponderance among anencephalies seen in humans (20 ). The Cd gene has been mapped to mouse chromosome 6 but remains to be identified ( 19).
Prenatal dietary supplementation with folic acid causes a reduction in the percentage of affected Cd embryos and provides the first model for a dietary response to folic acid ( 19). A reduction in the risk of exencephaly has been reported for folate-controlled diets containing 0 mg/kg (folate free) and 10 mg/kg compared with a baseline 4 mg/kg folic acid treatment. One possible explanation for this surprising result is that at 0 mg/kg, the majority of exencephalic embryos die early in gestation, yielding a low NTD frequency, whereas at 4 mg/kg, most embryos are rescued from early lethality but still develop exencephaly, yielding an apparently higher NTD frequency. Because parallel data were not reported for control embryos, it is not clear whether Cd homozygotes are particularly prone to die in folic-acid-deficient conditions. Cd may provide a useful model for NTD in humans and it will be of interest to determine whether there is an underlying defect in folate uptake or metabolism. In addition, because embryos in the initial study were collected at E12.5-14.5, it is important to test whether "rescued" embryos are viable postnatally and whether less severe defects may persist after folate treatment.
Folic-Acid-Binding Protein Knockout
Knockout mice have been generated for folic-acid-binding proteins, folbp 1 and folbp2, the murine homo logs of human folate receptors a and ~. respectively (9, 21, 22) . Folbp1 is a high-affinity integral membrane receptor responsible for transport of folate into the cytoplasm, whereas folbp2 is a low-affinity, glycosylphosphatidylinositol (GPI)-anchored receptor (23 ).
The genes encoding both proteins are expressed embryonically, suggesting that they could be involved in mediating the effect of folic acid during development (24 ) .
Homozygous null embryos for folbp 1 are severely growth retarded, fail to complete axial rotation, and die in utero, whereas folbp2 null mice are viable (22) . The specific effect of fo1bp I absence on neural tube closure cannot be determined from this study, as null embryos do not develop to a morphological stage at which the neural tube should have closed. It is clear, however, that folbp 1 is essential for normal development, probably to maintain sufficient cytoplasmic folate levels to meet metabolic requirements. The uptake of folate may also be suboptimal, but sufficient for normal development, in folbp2 mutants and folbpl and folbp2 heterozygotes. For example, although mice of these genotypes are apparently phenotypically normal, nonpregnant mice do show an abnormal response to folate deficiency. A folic-acid-deficient diet causes an increase in plasma homocysteine in wildtype mice, but this increase is significantly greater in mutants. Because elevated homocysteine is a risk factor for NTD, the offspring of such mice could be susceptible to develop NTD, perhaps in the presence of additional genetic or environmental factors. Therefore, it may be revealing to generate compound mutants of folbp knockouts with other folate-related mouse mutants.
Oral supplementation of heterozygous folbp I females with folinic acid prior to and during pregnancy led to the survival to late gestation of some homozygous offspring (22) . Litters were not collected until E18, when nonviable embryos would have been resorbed, so the proportion of rescued embryos could not be measured. Neither was the viability of rescued mice determined. Although the surviving folbp 1 null homozygotes in this study do not exhibit NTD, it is not clear whether this represents the prevention of NTD by folinic acid or prolongation of survival, enabling otherwise normal neural tube closure to progress to completion.
Splotch
Splotch mutant mice (Sp) are so called owing to the characteristic white belly spot of heterozygotes, which results from a neural-crest-related pig-mentation defect (25 ). Homozygous mutants exhibit a range of neural-crestrelated abnormalities, limb muscle defects, and neural tube defects, the latter comprising both exencephaly and spina bifida.
A proportion of homozygous embryos die around E14 as a result of heart defects (25,26). The Sp and Sp 2 H mutant alleles cause similar phenotypes and encode defective copies of the Pax3 gene (27) (28) (29) . Pax3 is a transcription factor containing both paired-box and homeobox DNA-binding motifs. It is expressed in the dorsal neural tube, migrating neural crest, and dermomyotomal cells (30-32) .
Mutations in the human PAX3 gene are found in Waardenburg syndromes types I and III in which there is a characteristic pigmentation defect ( 33,34 ) . The occurrence of isolated NTD in heterozygous Waardenburg patients and in a suspected homozygous case shows that the splotch mouse may provide a useful model forNTD (35, 36) . However, PAX3 mutations do not appear to contribute directly to a large proportion of human NTD (37, 38) . Interestingly however, it has recently been shown that the PAX3 protein may be implicated in human DiGeorge syndrome, through binding to the candidate HIRA protein ( 39 ). This emphasizes the general principle that genes may be involved in human developmental defects in ways other than by direct mutation. In this case, misregulation of PAX3 binding may contribute to the neural crest phenotype of DiGeorge syndrome.
Splotch provides the first mouse model in which NTD are preventable by folic acid in association with a demonstrable abnormality of embryonic folate metabolism ( 15). Abnormal folate metabolism was detected in wholeembryo culture using the deoxyuridine ( dU) suppression test. Incorporation of eH]thymidine into DNA is suppressed by exogenous dUMP owing to the activation of thymidylate synthase that catalyzes the de novo synthesis of dTMP (Fig. 1, reaction 2 ) from dUMP and 5,10-methylene tetrahydrofolate (5,10-MeTHF). The degree of suppression by dUMP is diminished if folate metabolism is compromised, because the supply of 5,10-MeTHF then becomes limiting. For instance, the application of folate cycle inhibitors leads to diminished dU suppression in mouse embryos (15). Two abnormalities of the dU test are observed in homozygous splotch embryos (15). First, in the absence of exogenous dUMP there is an increased incorporation of eH]thymidine in splotch homozygotes compared with wild-type embryos. Heterozygotes exhibit an intermediate level of [ 3 H]thymidine incorporation. Second, the extent of suppression is significantly diminished in homozygotes compared with heterozygotes and wild-type embryos. These observations indicate that the supply of 5,10-MeTHF is insufficient to meet the developmental requirements of splotch embryos.
Treatment with folic acid reduces the incidence of cranial and spinal NTD both in embryo culture and following maternal treatment by intraperitoneal injection ( 15). There is also a corresponding normalisation of the excessive [ 3 H]thymidine incorporation in splotch embryos following culture in the presence of folic acid. Therefore, in this model, prevention of NTD by folic acid appears to be associated with the correction of an underlying abnormality of folate metabolism (15, 40 ) .
A proportion of heterozygous splotch embryos, that normally complete cranial tube closure successfully, exhibits cranial NTD following methionine treatment in embryo culture. This apparent increase in the penetrance of the splotch defect is also associated with a further increase in the incorporation of thymidine, suggesting that methionine exacerbates the underlying folate abnormality ( 15 ). As described earlier, Axd mutants also exhibit occasional exencephaly following maternal methionine treatment, although methionine was curative with respect to the spinal defect ( 13 ). Methionine may, therefore, have a general inhibitory effect on cranial neural tube closure, which then causes NTD in predisposed embryos. Such an effect could be mediated through suppression of the folate cycle. For example, the presence of excess methionine inhibits synthesis of thymidylate ( 41 ), which is required for DNA synthesis.
COMPLEX GENETIC MODELS
Although a number of single-gene defects cause NTD in mutant mouse strains, the apparently spontaneous occurrence of most human NTD suggests that the majority are likely to arise as multigenic traits: for instance, when two or more independently segregating, mutant alleles are inherited together, each individually has only a low probability of inducing NTD. As the number of genetically defined mutant mouse strains increases, it is becoming possible to test the combined effect of multiple-gene defects by cross-breeding mice that carry different combinations of mutations.
Patch/Undulated
The Pax] transcription factor gene is mutated in undulated mice ( 42 ), whereas the platelet-derived growth factor receptor a (Pdgfra) gene is deleted in patch mice ( 43 ). Double-mutant mice (unlun Phi+) develop spina bifida occulta, a novel skeletal phenotype that is absent in both single-gene mutants (44), although Ph homozygotes are reported to have occasional NTD (45). The effect of folate supplementation has not been tested in these compound mutants.
Splotch/Curly Tail
Spinal NTD arise in splotch and curly tail mice as a result, respectively, of mutations in Pax3 and an as-yet unidentified gene mapping to the distal region of chromosome 4 (28,46) . The phenotype of double mutants indicates that the mutations interact to increase the risk of spinal NTD (47). In double heterozygotes, there is a 10% incidence of tail defects, although single heterozygotes for splotch or curly tail are unaffected (25, 26, 48) . Embryos of genotype Spl+,ct/ct exhibit a significantly higher incidence of spinal defects, spina bifida, and tail defects.
Although the increased risk of NTD suggests that there is a modifier effect in the genetic sense, neither the splotch nor curly tail defect seems to be worsened at the developmental level in double mutants. NTD in curly tail arise from delayed closure of the posterior neuropore (PNP) that results from excessive ventral curvature of the caudal part of the embryo (49, 50) . In double mutants, there is no apparent increase in the mean ventral curvature, suggesting that the curly tail defect is not directly affected. In splotch, NTD are accompanied by neural-crest abnormalities that cause small or absent dorsal root ganglia (25). However, double mutants exhibit no abnormalities of dorsal root ganglia suggesting that splotch heterozygotes have not been pushed toward the homozygous phenotype by the presence of the curly tail mutation ( 47). Therefore, the Pax3 and curly tail mutations summate to produce NTD, an example of digenic inheritance analogous to that described for undulated/patch mice.
Neural tube defects in splotch are preventable by folic acid ( 15), whereas NTD in curly tail mutant mice do not respond to folic acid ( 4) but are preventable by another vitamin, inositol (51), with no abnormalities of folate metabolism ( 15 ). It will be interesting to determine whether the NTD that arise as a result of interaction of the two mutations are preventable by folic acid or inositol or whether both agents are required. Such data may indicate whether combined folic acid and inositol supplementation should be considered for human trials.
Splotch/NF1
A genetic interaction has also been demonstrated between Pax3 (splotch) and NF 1 mutations. NF 1 is a tumor suppressor gene that encodes neurofibromin, a protein with homology to the GTPase-activating protein family, which downregulates RAS activity. Mutations in NF 1 are associated with neurofibromatosis in humans (52). In NFJ knockout mice, there is a low incidence of exencephaly, which appears to principally affect females (53). Heterozygotes are morphologically normal but do have behavioral abnormalities associated with learning deficits (54) .
NF ]/splotch double mutants were generated by mating splotch and NF 1 null heterozygotes and then intercrossing the doubly heterozygous offspring. Among the offspring of this F2 generation, 100% of embryos homozygous for the splotch mutation developed NTD comprising exencephaly and/or spina bifida. Double homozygous embryos did not survive beyond E11.5 and all of the embryos at that stage had severe exencephaly and spina bifida, suggesting a possible interaction between the mutations. Moreover, among compound heterozygotes examined at E11.5, there was an approx 10% incidence of NTD, which do not occur in single heterozygotes for either mutation. Therefore, it is proposed that NF1 is a modifier gene for splotch (53). The effect of folic acid therapy has not been tested in these double mutants (Table 1) .
Alx4/Cart1
Homozygous Alx4 knockout mice exhibit preaxial polydactyly, a ventral body-wall defect and delayed formation of the parietal bone (55). Like Cart] mutants, heterozygotes are unaffected. Alx4 and Cart] both encode transcription factors of the family that contain a paired-type homeodomain without a paired domain (16, 56) and are both expressed predominantly in mesenchymal cells.
Although the mutant phenotypes are nonoverlapping, the production of compound mutants reveals interactions between the genes. The Cart] mutation exacerbates the polydactyly phenotype of the Alx4 mutant in a dosedependent manner (57). Moreover, the craniofacial phenotype of Cart] homozygotes is modified by the presence of the Alx4 mutation in heterozygous or homozygous form, giving rise to a cleft face, a defect that may reflect suppression of "Closure 3," the most rostral site of neural tube closure (58) . In addition, craniofacial abnormalities not observed in either single mutant also occur in Alx4-1 -, Cart]+!-double mutants. Double homozygotes also exhibit a split sternum that is not present in either single mutant (57). Therefore, the gene mutations each modify the effect of the other and they also interact to cause novel phenotypes. The effect of folate supplementation on Alx4 defects has not been evaluated. If defects are not responsive, it will be particularly interesting to test the effect of folate treatment in Alx4/Cartl double mutants. Folate treatment may prevent the novel phenotype caused by the interaction of the two mutations. In addition, where Cart] acts as a modifier of the Alx4 phenotype, it will be interesting to determine whether folate treatment can have a protective effect through a folate-responsive modifier gene as opposed to an action directly on the primary defect.
GENETIC BACKGROUND EFFECTS
As in humans, genetic polymorphisms affect the incidence of NTD in mice. This is indicated by the strain-dependent variation in penetrance of NTD caused by gene mutations such as Cart] ( 17) and teratogens such as valproic acid (59, 60) . In several cases, folate metabolism has been implicated in the pathogenetic mechanism or as a protective agent.
One mechanism for the genetically determined susceptibility to neural tube defects is suggested by the observation that the initial cranial site of closure (Closure 2) varies among inbred strains of mice (61). A more rostral location of this closure site confers a greater susceptibility to cranial NTD (62). For instance, the mutation in the Pax3 gene carried by the splotch (Sp 2 H) allele causes a high incidence of cranial NTD when transferred, by breeding, onto a strain background with a rostral site of Closure 2. In contrast, the incidence is reduced on a strain background with a more caudal closure site (62). A control backcross that does not alter the site of Closure 2 does not affect the incidence of cranial NTD. The correlation of the closure site with NTD risk also holds for defects induced by teratogens such as valproic acid (59,63) and hyperthermia (64).
A strain-dependent variation in penetrance of a genetic mutation suggests the presence of modifier genes that are polymorphic or differentially expressed between strains. The ability to breed mutations onto different inbred genetic backgrounds facilitates the identification of such modifiers, either by backcross and haplotype analysis or by direct comparison of differential gene expression between the strains. A backcross approach was used to map a modifier gene for the curly tail defect, met], to chromosome 17 (65). Differential expression of gas5 between strains has been proposed to indicate its potential role as a modifier for susceptibility to heat-induced defects (66).
FOLATE-INSENSITIVE GENETIC MODELS
Although clinical trials clearly demonstrate that folic acid supplementation reduces the incidence of NTD, there remains a significant proportion of human NTD [approx 30% in the Medical Research Council {MRC} trial (67)] that do not appear to respond to folate. It is therefore important to consider additional, folate-insensitive, mouse models in order to understand the pathology and possible prevention of this group of defects.
Curly Tail
Homozygous curly tail embryos exhibit a low-frequency of exencephaly in addition to a higher incidence of spinal NTD and tail flexion defects that result from delayed closure of the posterior neural tube ( 48, 50 ) . NTD show partial penetrance, with variable expressivity on different genetic backgrounds (46). In this mutant, the defect underlying the development of spinal NTD has been identified as a reduction in cell proliferation in the ventral tissues, hindgut, and notochord (68) . The consequent growth imbalance between the ventral tissues and the neural plate causes excessive ventral curvature of the caudal region of the embryo that mechanically opposes closure of the posterior neuropore ( 49 ).
Although several features of curly tail resemble spinal NTD in humans (69) [e.g., the female preponderance among exencephalics (70,71)], there is no preventive effect of folic acid or other folate metabolites including methionine ( 4, 72 ) . Therefore, curly tail may represent a useful model for folateinsensitive NTD (40). Neural tube closure in curly tail has proven to be sensitive to the level of a different vitamin, inositol. Curly tail embryos are particularly sensitive to inositol deficiency and develop a high incidence of exencephaly when cultured in medium lacking inositol (73). In addition, inositol supplementation in vivo or in vitro reduces the incidence of spina bifida resulting from normalization of posterior neuropore closure (51). The effect of inositol is mediated through the inositol/lipid cycle and involves activation of protein kinase C (51), the exact isoforms of which are currently under investigation. It is proposed that inositol supplementation may also prevent some cases of human NTD that do not respond to folic acid, although the prediction has not yet been tested in a formal clinical study.
ENVIRONMENTAL MODELS
A number of environmental factors have been associated with folate-preventable NTD. Animal models provide the opportunity to analyze the effect of such factors against a uniform genetic background, enabling isolation of the factor under analysis.
Folate Deficiency
Human studies indicate that maternal folate deficiency is a risk factor for NTD (74 ) , although it is thought unlikely that folate supplementation reduces the incidence ofNTD by simply correcting a dietary deficiency (75) (76) (77) . Similarly, folate deficiency is not sufficient to cause NTD in mice either in utero or in whole-embryo culture.
The effect of maternal folate deficiency on embryonic development has been studied using amino-acid-based diets in which the folate level was strictly controlled (78) . At levels below a 906-nmol/kg diet, there was a high proportion of resorptions and the embryos that did develop were smaller than controls, but otherwise developed normally, without NTD. Folate deficiency has also been induced in rat whole-embryo culture using medium consisting of rat serum that had been extensively dialyzed to remove small molecules and then supplemented with glucose, amino acids, and vitamins (79, 80) . Absence of folic acid from the medium causes generalized growth retardation but does not cause NTD. In contrast, deficiency of inositol, a vitamin that is capable of preventing NTD in a folate-insensitive mouse model (51), causes NTD in mouse and rats (73, 79) . It is possible that embryos may have a sufficient pool of intracellular folate to counteract the period of deficiency. Alternatively, some folate may remain in the dialyzed serum because of sequestration by binding proteins. Whatever the explanation, this study indicates that mouse embryos are relatively resistant to shortterm deficiency of folate in terms of neural tube closure.
Folate Cycle Metabolites Homocysteine
Elevated level of homocysteine in maternal serum is a risk factor for NTD in humans, suggesting that excess homocysteine may itself be deleterious (81) (82) (83) . Exposure of chick embryos to D,L-homocysteine or L-homocysteine thiolactone causes NTD, ventricular septal defects, and ventral closure defects (84) . In contrast, homocysteine treatment of cultured rat embryos does not cause NTD, although it is toxic at high doses (85). These toxic effects can be reduced by concurrent treatment with 5-methyl tetrahydrofolate (THF) and serine that may act to promote the metabolic removal of homocysteine. Serine is the one carbon donor for formation of 5,10-methylene THF (Fig. 1, reaction 3) , a precursor of 5-methyl THF that, in tum, is the carbon unit donor for remethylation of homocysteine by methionine synthase (Fig. 1, reaction 1) . Serine is also required for removal of homocysteine by transulfuration, generating cystathionine (Fig. 1, reaction 4) . However, the enzyme cystathione ~ synthase, which catalyses this reaction, may not be present in the neurulation-stage embryo (86).
Conversely, the harmful effect of homocysteine may result from indirect inhibition ofthymidylate synthase, the enzyme that catalyzes the production of dTMP. Increased demand for 5-methyl THF by methionine synthase would reduce the level of 5,10-methylene THF, a substrate for dTMP production (Fig. 1, reaction 2) . Moreover, diversion of serine to the transulfuration pathway would also limit its availability for synthesis of 5,10-methylene THF. In support of this idea, cell culture studies suggest that excess homocysteine leads to inhibition of thymidylate synthase (41) .
A third possibility is that raised levels of s-adenosyl homocysteine (SAH) that may occur under conditions of homocysteine excess could inhibit critical methylation reactions (Fig. 1, reaction 5 ) in the embryo. Further studies in animal model systems should address these possibilities.lt is important to note, however, that the levels of homocysteine that have proven toxic in vitro are significantly higher than those measured in human maternal serum or amniotic fluid. This suggests that in the human cases, raised homocysteine alone is unlikely to be teratogenic but could be a marker of NTD risk or could interact with other genetic or environmental factors to contribute to the development of defects.
Methionine
In different experimental situations, methionine supplementation can be beneficial or harmful. In embryo culture studies, using suboptimal culture conditions based on cow serum (87, 88) , human serum (85), or the presence of antibodies to the visceral yolk sac ( 89 ), embryos exhibit growth retardation and abnormalities including cranial NTD. In each of these cases, methionine supplementation has an ameliorating effect. The relationship to folate metabolism per se appears to be indirect, as in the latter two cases, folinic acid or 5-methyl THF, do not have the same effect.
As described earlier, methionine increases the frequency of NTD in splotch mice in which folate metabolism is compromised ( 15). The mechanism of methionine action in splotch embryos remains unclear but could result from methionine inhibition of thymidylate synthase ( 89 ). This would limit the availability of dTMP and exacerbate the excess requirement for dTMP in splotch embryos. Alternatively, there could be increased flux through the methionine cycle with possible accumulation of deleterious intermediates, including homocysteine, as discussed earlier, or s-adenosyl methionine, which may hamper the remethylation of homocysteine via inhibition of MTHFR (Fig. 1, reaction 6 ) (90).
Folate Cycle Antagonists
In humans, there is an increased risk of fetal loss and malformations in the offspring following treatment during pregnancy with folate cycle antagonists, including 5-fluorouracil and methotrexate (91, 92) . Defects include cleft lip and palate, craniofacial malformations, and limb abnormalities, as well as NTD.
5-Fluorouracil: Inhibitor of Thymidylate Synthase
In mice, maternal treatment with 5-fluorouracil (5-FU) also causes limb and craniofacial defects in the embryo (93, 94) . In these studies, the effect on neural tube closure was not determined, as treatment was from E10 or E14, after the period of closure. Because 5-FU inhibits thymidylate synthase (Fig.  1, reaction 2) , a key enzyme in supplying precursors for pyrimidine biosynthesis, it will be interesting to determine the effect of 5-FU on neural tube closure. The potential protective effect of folic acid against 5-FU-induced defects remains to be tested.
Nitrous Oxide: Inhibitor of Methionine Synthase
Methionine synthase is a key enzyme that links the folate cycle with the methionine/homocysteine cycle, catalyzing the remethylation of homocysteine to methionine (Fig. 1, reaction 1 ) . Inhibition of methionine synthase is predicted to be deleterious in several respects, including the accumulation of potentially teratogenic homocysteine and depletion of methionine thus reducing the supply of s-adenosyl methionine for trans-methylation reactions (Fig. 1, reaction 5) . As described previously, elevated level of homocysteine is a risk factor for NTD (82) . Diminished methionine synthase activity is also predicted to lead to reduced production ofTHF which could, in tum, limit the availability of 5,10-methylene THF (Fig. 1, reaction 3) , a requirement for dTMP and pyrimidine synthesis. Genetic studies in humans have so far failed to demonstrate a linkage between the methionine synthase gene and predisposition to NTD (37, 95) .
Methione synthase can be inhibited in rat embryos by exposure of pregnant females, and, subsequently, embryos in culture, to nitrous oxide. This results in decreased synthesis of dTMP from the folate cycle and increased incorporation of labeled thymidine, via the "salvage" pathway ( Fig. 1, reaction 7) , from the culture medium (96) . In terms of embryonic development, nitrous oxide treatment in embryo culture causes generalized growth retardation and axial malformations but does not cause NTD (97) . The adverse effects of nitrous oxide appear to result from methionine depletion, as they can be prevented by concurrent supplementation with methionine, but not with folic acid (98) .
Maternal Heat Exposure
Maternal exposure to elevated temperatures early in pregnancy is another risk factor for NTD (99) . Exposure to brief periods of hyperthermia in humans can result from fever or recreational use of hot tubs or saunas and all have been linked to an increased risk of NTD in epidemiological studies. Laboratory animals, including mice, are also susceptible to hyperthermiainduced teratogenesis ( 100). Exposure of pregnant mice to hyperthermia at E8.5, the stage at which the cranial neural tube is closing, causes a high incidence of cranial NTD (exencephaly and anencephaly) ( 101), which can be suppressed by maternal supplementation with folic acid during pregnancy. It is proposed that heat exposure may cause a transient reduction in cell proliferation that is overcome by folic acid (101). Interestingly, in the same study, supplementation with myo-inositol also caused a reduction in the incidence of heat-induced NTD, although this was not statistically significant.
The susceptibility to heat-induced NTD is influenced by the genetic background in different mouse strains (64). Owing to its strain-specific expression pattern, the growth arrest specific (gas5) gene has been suggested as a possible determinant of varying NTD susceptibility in the SWV /Fnn and LM/Bc/Fnn strains (66). It seems likely, however, that the rostral position of the site of anterior neural tube closure (Closure 2) in the SWV strain is also a major predisposing factor compared with the more caudal site of Closure 2 in the less susceptible LM/Bc strain (61, 62) . Whether expression of gas5 influences the site of Closure 2 remains to be determined.
Valproate
In humans, it is clear that there is an increased risk of NTD, particularly spina bifida, following maternal treatment with the anticonvulsant valproic acid (VPA) ( 102). In mice, maternal VPA treatment is embryotoxic, causing growth retardation and abnormalities that include skeletal defects and NTD, the precise phenotype depending on embryonic age at the time of treatment. VPA administration on E8 or E9 induces exencephaly and spina bifida, respectively (103,104). These outcomes reflect the level of the body axis undergoing neural tube closure in the period immediately following VPA administration. At lower doses, the skeletal malformations appear to represent homeotic transformations of the vertebral column (60) . In cultures of rat or mouse embryos, VP A also causes cranial and caudal NTD as well as growth retardation and abnormalities of otic and optic vesicles and neuroepithelial ultrastructure ( 105-108) .
The relationship of VPA-induced teratogenicity to folate metabolism is controversial. In mice, maternal treatment with folinic acid (5-formyl tetrahydrofolate) has been reported to reduce the incidence ofVPA-induced exencephaly ( 109, 110) . In contrast, folinic acid was not protective in separate studies and neither was folic acid nor 5-methyl THF ( 107). Despite the inconsistent results from folate treatment, the levels of several folate metabolites are altered in VPA-treated embryos, whereas a nonteratogenic analog of VPA does not have this effect (I 10,111 ) . Following VPA treatment, the levels of 5-formyl-THF (folinic acid) and 10-formyl-THF decrease, whereas the level of THF increases, suggesting that the enzyme glutamate formyltransferase (Fig. 1, reaction 8 ) is inhibited by VPA (110) . Whether this effect is related to the induction of NTD is unclear.
Additional studies suggest that methionine may have a protective effect against VPA teratogenesis. Intraperitoneal injection of methionine into pregnant mice reduces the rate of spina bifida occulta induced by VP A treatment on E9 ( 112). On the other hand, methionine treatment of rat embryos in culture does not reduce the incidence of VPA-induced abnormalities ( 113, 114 ) , indicating that the action of methionine in vivo may be mediated through an effect on maternal metabolism, rather than correcting a methionine deficiency in the embryo per se. Indeed, maternal VPA treatment reduces plasma methionine levels and increases homocysteine and cysteine levels ( 111 ), consistent with this hypothesis. Moreover, if the rats used as serum donors or embryo donors receive prior dietary supplementation with methionine, this does provide a significant protective effect against VP Atreatment in embryo culture ( 113).
Several studies have addressed the possible mechanism for VPA-induced defects in terms of altered gene expression. For example, the induction of of homeotic transformations may be associated with altered expression of Hox genes (60), whereas several transcription factors, including Emx-1, Emx-2, c-fos, c-jun, and creb, appear to be upregulated following VPA treatment (115). However, is unclear whether these genes are significant in VPA-induced pathogenesis or merely part of a global misregulation of gene expression. Further analysis of gene expression following VPA treatment suggests that differences in the response of folate-related genes may be involved in the strain-specific sensitivity to VPA. Following VPA treatment, folatebinding protein-1 expression is reduced in SWV, a sensitive strain, whereas it is upregulated in the less sensitive LM/Bc strain. LM/Bc embryos also express MTHFR at a higher level ( 116). These two differences may enable LM/Bc embryos to respond more effectively than SWV embryos to altered levels of folate metabolites following VP A treatment. In a much wider screen, RNA probes from VPA-treated and untreated tissues were used to screen a eDNA library derived from neural tube from the region of Closure 2. The gene-encoding ribonucleotide reductase subunit R1 (rnr-r 1 ), a cell cycle regulatory protein, was found to be upregulated following VPA treatment, correlating with a decrease in cellular proliferation in the region of neural tube where Closure 2 occurs in normal untreated embryos ( 117). Because growth retardation predisposes to the development of NTD in several other mouse models (1 ), it is possible that upregulation of rnr-r 1 may be part of the pathogenetic mechanism leading from VPA treatment to cranial NTD.
